Squarepoint Ops LLC Verve Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $47,552 - $127,772	-9,990 Reduced 11.92%	73,810 $360,000
Q1 2024 May 15, 2024	SELL	$10.81 - $17.96 $1.74 Million - $2.89 Million	-160,885 Reduced 65.75%	83,800 $1.11 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $2.03 Million - $4.29 Million	229,517 Added 1513.17%	244,685 $3.41 Million
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $1.47 Million - $2.19 Million	-110,272 Reduced 87.91%	15,168 $284,000
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $1.19 Million - $1.99 Million	82,945 Added 195.19%	125,440 $1.81 Million
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $758,535 - $1.73 Million	42,495 New	42,495 $822,000
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $122,929 - $255,680	11,035 Added 37.56%	40,417 $618,000
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $614,671 - $1.16 Million	29,382 New	29,382 $670,000
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $1.44 Million - $2.31 Million	-31,253 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $997,595 - $1.88 Million	31,253 New	31,253 $1.88 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.